File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41467-022-28068-3
- Scopus: eid_2-s2.0-85123176091
- PMID: 35058463
- WOS: WOS:000745469500002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
Title | Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong |
---|---|
Authors | |
Issue Date | 2022 |
Publisher | Nature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/ncomms/index.html |
Citation | Nature Communications, 2022, v. 13 n. 1, p. article no. 411 How to Cite? |
Abstract | Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination. |
Persistent Identifier | http://hdl.handle.net/10722/310145 |
ISSN | 2023 Impact Factor: 14.7 2023 SCImago Journal Rankings: 4.887 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lai, FTT | - |
dc.contributor.author | Huang, L | - |
dc.contributor.author | Chui, CSL | - |
dc.contributor.author | Wan, EYF | - |
dc.contributor.author | Li, X | - |
dc.contributor.author | Wong, CKH | - |
dc.contributor.author | Chan, EWW | - |
dc.contributor.author | Ma, T | - |
dc.contributor.author | Lum, DH | - |
dc.contributor.author | Leung, JCN | - |
dc.contributor.author | Luo, H | - |
dc.contributor.author | Chan, EWY | - |
dc.contributor.author | Wong, ICK | - |
dc.date.accessioned | 2022-01-24T02:24:31Z | - |
dc.date.available | 2022-01-24T02:24:31Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Nature Communications, 2022, v. 13 n. 1, p. article no. 411 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | http://hdl.handle.net/10722/310145 | - |
dc.description.abstract | Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination. | - |
dc.language | eng | - |
dc.publisher | Nature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/ncomms/index.html | - |
dc.relation.ispartof | Nature Communications | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong | - |
dc.type | Article | - |
dc.identifier.email | Lai, FTT: fttlai@hku.hk | - |
dc.identifier.email | Huang, L: leihuang@hku.hk | - |
dc.identifier.email | Chui, CSL: cslchui@hku.hk | - |
dc.identifier.email | Wan, EYF: yfwan@hku.hk | - |
dc.identifier.email | Li, X: sxueli@hku.hk | - |
dc.identifier.email | Wong, CKH: carlosho@hku.hk | - |
dc.identifier.email | Chan, EWW: edwwchan@hku.hk | - |
dc.identifier.email | Lum, DH: dawnlum@hku.hk | - |
dc.identifier.email | Leung, JCN: leungjcn@hku.hk | - |
dc.identifier.email | Luo, H: haoluo@hku.hk | - |
dc.identifier.email | Chan, EWY: ewchan@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.authority | Lai, FTT=rp02802 | - |
dc.identifier.authority | Chui, CSL=rp02527 | - |
dc.identifier.authority | Wan, EYF=rp02518 | - |
dc.identifier.authority | Li, X=rp02531 | - |
dc.identifier.authority | Wong, CKH=rp01931 | - |
dc.identifier.authority | Luo, H=rp02317 | - |
dc.identifier.authority | Chan, EWY=rp01587 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/s41467-022-28068-3 | - |
dc.identifier.pmid | 35058463 | - |
dc.identifier.pmcid | PMC8776841 | - |
dc.identifier.scopus | eid_2-s2.0-85123176091 | - |
dc.identifier.hkuros | 331579 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. 411 | - |
dc.identifier.epage | article no. 411 | - |
dc.identifier.isi | WOS:000745469500002 | - |
dc.publisher.place | United Kingdom | - |